(Reuters) – AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the United States as a therapy for patients with previously treated HER2-positive advanced gastric cancer, the British drugmaker said on Monday.
The company said the approval by the U.S. Food and Drug Administration was based on results from the DESTINY-Gastric01 trial conducted in Japan and South Korea.
(Reporting by Tanishaa Nadkar in Bengaluru; Editing by Arun Koyyur)
